Bright Minds Biosciences Inc. (C:DRUG)
Business Focus: Biotechnology & Medical Research (NEC)
Dec 06, 2023 04:08 pm ET
Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/
Aug 08, 2023 06:50 am ET
Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders and refractory epilepsy, today announced...
Jul 20, 2023 06:50 am ET
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders and refractory epilepsy, today announced...
Jul 12, 2023 10:33 am ET
CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)
Toronto, Ontario--(Newsfile Corp. - Le 12 juillet/July 2023) - Bright Minds Biosciences Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every five (5) pre-consolidated common shares.
Jul 11, 2023 06:50 am ET
Bright Minds Announces Effective Date of Share Consolidation
Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that,...
Jun 22, 2023 06:50 am ET
Bright Minds Announces Proposed Share Consolidation
Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that it...
Apr 19, 2023 06:50 am ET
Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that...
Apr 10, 2023 06:50 am ET
Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that...
Feb 27, 2023 06:50 am ET
Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today provided an...
Feb 17, 2023 06:50 am ET
Bright Minds Biosciences Announces Non-Executive Director Appointment
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the...
Feb 08, 2023 04:05 pm ET
Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a letter (the “Deficiency Letter”) from the Nasdaq Stock Market LLC (“NASDAQ”) dated February 2, 2023, stating that following...
Jan 27, 2023 04:05 pm ET
Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a notification letter (the “Notification Letter”) from the Nasdaq Stock Market LLC (“NASDAQ”) dated January 26, 2023, notifying...
Jan 09, 2023 04:05 pm ET
Bright Minds Biosciences Announces Resignation of Board Member
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Dec 02, 2022 07:06 pm ET
Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) is pleased to announce that, further to its news release on November 28, 2022, it has closed a non-brokered private placement of (i) 666,000 pre-funded...
Nov 28, 2022 06:50 am ET
Bright Minds Biosciences Announces Non-Brokered Private Placement
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) is pleased to announce a non-brokered private placement of (i) pre-funded warrants of the Company (“PFWs”) at a price of $1.249 per PFW (the “PFW Offering”),...
Nov 23, 2022 11:35 am ET
Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Sep 07, 2022 06:50 am ET
Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Aug 31, 2022 06:50 am ET
Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Aug 30, 2022 03:35 pm ET
Bright Minds Biosciences Announces Closing of $4 Million Unit Offering
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) is pleased to announce that it has closed its previously announced overnight marketed offering (the “Offering”) of 2,858,000 units of the Company at a price of...
Aug 23, 2022 09:06 pm ET
Bright Minds Announces Pricing of Overnight Marketed Offering of Units
Bright Minds Biosciences Inc. (“Bright Minds” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, is pleased to announce...
Aug 22, 2022 07:05 pm ET
Bright Minds Announces Overnight Marketed Offering of Units
Bright Minds Biosciences Inc. (“Bright Minds” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, is pleased to announce...
Aug 18, 2022 03:33 pm ET
Bright Minds Biosciences Comments on Recent Trading Activity
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, is issuing this news...
Jun 27, 2022 06:50 am ET
Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
May 12, 2022 06:50 am ET
Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
May 02, 2022 06:50 am ET
Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Apr 19, 2022 06:50 am ET
Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Mar 14, 2022 06:50 am ET
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Mar 08, 2022 07:30 am ET
Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Jan 04, 2022 04:05 pm ET
Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Dec 15, 2021 05:13 pm ET
Canadian Securities Exchange's November 2021 Performance Includes Strong Listings Growth and New Financing Milestone
Toronto, Ontario--(Newsfile Corp. - December 15, 2021) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced its market statistics for the month of November 2021, which was highlighted by near-record listings growth and a new financing milestone.
Dec 06, 2021 06:50 am ET
Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Nov 30, 2021 07:30 am ET
Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today provided a...
Nov 03, 2021 06:50 am ET
Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that...
Oct 18, 2021 08:35 am ET
KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Oct 18, 2021 08:35 am ET
KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing
NEW YORK, Oct. 18, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.
Oct 11, 2021 09:25 am ET
KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th
Psychedelic and CNS Company Executives share vision, answer questions live at VirtualInvestorConferences.com
Oct 07, 2021 08:35 am ET
Bright Minds Biosciences Inc. to Webcast Live At VirtualInvestorConferences.com October 14th
NEW YORK, Oct. 7, 2021 /PRNewswire/ -- BRIGHT MINDS BIOSCIENCES INC. (CSE: DRUG/OTCIQ: BMBIF), based in New York focused on new approaches to neuroscience, today announced that Ian McDonald, President & CEO and Josh Blacher, VP of Corporation Development, will present live at VirtualInvestorConferences.com on October 14th.
Oct 06, 2021 06:50 am ET
Bright Minds Biosciences to Present at the LD Micro Main Event Small Cap Investment Conference
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that...
Sep 22, 2021 07:00 am ET
Bright Minds Biosciences Provides Scientific Update
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today provided an...
Sep 08, 2021 06:50 am ET
Bright Minds Biosciences to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference; Shares Now Eligible for DTC Clearance
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that...
Aug 18, 2021 07:00 am ET
Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that...
Jun 16, 2021 06:50 am ET
Bright Minds Biosciences Announces Application to List on Nasdaq
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain, is pleased to announce...
Jun 14, 2021 04:05 pm ET
Bright Minds Biosciences Appoints New Board Member and Expands Leadership Team
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced a new...
Jun 11, 2021 08:00 am ET
Bright Minds Biosciences to Present at the H.C. Wainwright Virtual Conference Psychedelics in Psychiatry and Beyond
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that Ian...
Jun 09, 2021 04:30 pm ET
Bright Minds Biosciences to Present at the 2021 LD Micro Invitational XI
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that Ian...
May 17, 2021 06:50 am ET
Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture Market on May 17, 2021
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that its...
May 11, 2021 08:00 am ET
Bright Minds Biosciences to Present at the Benzinga Global Small Cap Conference
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that Ian McDonald, Chief...
Apr 27, 2021 08:00 am ET
Bright Minds Biosciences Appoints Industry Experts for Key Roles and Expands Scientific Advisory Team
Bright Minds Biosciences (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced two additions to its leadership team and one...
Mar 17, 2021 12:30 pm ET
Bright Minds Biosciences Announces Closing of $25.9 Million Unit Offering
Bright Minds Biosciences Inc. (CSE:DRUG) (“Bright Minds” or the “Company”) is pleased to announce that it has closed its previously announced underwritten public offering (the “Offering”) of units (the “Units”) of the Company. Eight Capital acted...
Mar 15, 2021 04:15 pm ET
Canadian Securities Exchange Shatters Previous Monthly Trading Volume Record
Toronto, Ontario--(Newsfile Corp. - March 15, 2021) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced its market statistics for the month of February 2021. The CSE substantially exceeded its previous monthly record for trading volume and value, while its issuers completed the second highest number of financings on record.
Mar 15, 2021 08:00 am ET
Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows an Over 50% Decrease in Opioid Self-Administration in a Predictive Rodent Model
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that studies conducted...
Mar 10, 2021 08:00 am ET
Bright Minds Biosciences to Present at the Stifel GMP Healthcare Conference - Healthcare Psychedelics: Addressing the Global Mental Health Crisis
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that Ian McDonald, Chief...
Mar 03, 2021 08:00 am ET
Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonists Show Significant Reduction in Binge Eating
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG), is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that studies conducted with its BMB proprietary...
Feb 23, 2021 12:20 pm ET
Bright Minds Biosciences Inc. Announces Pricing of Public Marketed Offering of Units
Bright Minds Biosciences Inc. (CSE:DRUG) (“Bright Minds” or the “Company”) announces the pricing of its previously announced underwritten marketed offering (the “Offering”) of an aggregate of 3,303,000 units of the Company (the “Units”) at a price...
Feb 23, 2021 11:37 am ET
IIROC Trade Resumption - DRUG
VANCOUVER, BC, Feb. 23, 2021 /CNW/ - Trading resumes in:
Feb 23, 2021 08:09 am ET
IIROC Trading Halt - DRUG
VANCOUVER, BC, Feb. 23, 2021 /CNW/ - The following issues have been halted by IIROC:
Feb 22, 2021 04:38 pm ET
Bright Minds Biosciences Inc. Announces Marketed Public Offering
Bright Minds Biosciences Inc. (CSE:DRUG) (“Bright Minds” or the “Company”) announces that it has commenced an underwritten marketed public offering (the “Offering”) of units of the Company (the “Units”). Each Unit is comprised of one common share...
Feb 10, 2021 08:00 am ET
Bright Minds Biosciences Strengthens Scientific Advisory Team to Prepare for Future Growth
Bright Minds Biosciences (“Bright Minds” or the “Company”), a biosciences company focused on creating the next generation of psychedelic and related therapies for the treatment of mental health and central nervous system disorders, today announced...
Feb 05, 2021 11:30 am ET
Bright Minds Biosciences Announces Listing on Canadian Stock Exchange
Bright Minds Biosciences (“Bright Minds” or the “Company”), a biosciences company focused on creating the next generation of psychedelic and related therapies for the treatment of mental health and central nervous system disorders, today announced...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
